In the past week, DNA stock has gone up by 13.38%, with a monthly gain of 10.55% and a quarterly surge of 37.79%. The volatility ratio for the week is 10.68%, and the volatility levels for the last 30 days are 12.14% for Ginkgo Bioworks Holdings Inc The simple moving average for the past 20 days is 6.67% for DNA’s stock, with a -38.14% simple moving average for the past 200 days.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
The 36-month beta value for DNA is at 1.09. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DNA is 36.49M, and currently, shorts hold a 19.66% of that float. The average trading volume for DNA on January 02, 2025 was 1.19M shares.
DNA) stock’s latest price update
The stock price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has surged by 8.19 when compared to previous closing price of 9.82, but the company has seen a 13.38% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-12-18 that – Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies – STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA’s synthetic DNA, Linea™ DNA, as a critical component in its manufacture.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at 21.07% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.56% of loss for the given period.
Volatility was left at 12.14%, however, over the last 30 days, the volatility rate increased by 10.68%, as shares surge +10.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.40% upper at present.
During the last 5 trading sessions, DNA rose by +14.62%, which changed the moving average for the period of 200-days by -75.37% in comparison to the 20-day moving average, which settled at $9.97. In addition, Ginkgo Bioworks Holdings Inc saw 8.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $9.97 back on Jan 02 ’25. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $987 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $9.53 during a trade that took place back on Dec 31 ’24, which means that Che Austin is holding shares at $943 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 0.64 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -2.99. The total capital return value is set at -0.43. Equity return is now at value -63.51, with -37.13 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -6358.49.
Currently, EBITDA for the company is -821.29 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.97. The receivables turnover for the company is 9.31for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.79.
Conclusion
In conclusion, Ginkgo Bioworks Holdings Inc (DNA) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
